

Hye Jin Choi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/438905/hye-jin-choi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96
papers

2,941
citations

26
h-index

52
g-index

100
ext. papers

3,541
ext. citations

4.9
avg. IF

4.52
L-index

#	Paper	IF	Citations
96	Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS490-TPS490	2.2	1
95	Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways.. <i>BMC Cancer</i> , 2022 , 22, 423	4.8	0
94	Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role. <i>Journal of Proteome Research</i> , 2021 , 20, 5315-5328	5.6	
93	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021 , 39, 1366-1374	4.3	2
92	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 3123-3133	4.9	1
91	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). <i>ESMO Open</i> , 2021 , 6, 100049	6	8
90	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , 2021 , 125, 200-208	8.7	5
89	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021 , 74, 350-359	13.4	51
88	Enhanced oncolytic adenoviral production by downregulation of death-domain associated protein and overexpression of precursor terminal protein. <i>Scientific Reports</i> , 2021 , 11, 856	4.9	0
87	Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211035983	5.4	1
86	Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses. <i>Hepatology</i> , 2021 , 74, 1914-1931	11.2	5
85	Pilot study for the Psychometric Validation of the Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2021 , 53, 25-31	5.2	1
84	Expression of Organic Anion Transporting Polypeptides in an H-Ras 12V Transgenic Mouse Model of Spontaneous Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021 , 62, 622-630	3	
83	Adjuvant radiotherapy and chemotherapy offer a recurrence and survival benefit in patients with resected perihilar cholangiocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2435-2445	4.9	2
82	Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF Mutation-Positive Malignancies. <i>Clinical Pharmacology in Drug Development</i> , 2020 , 9, 651-658	2.3	1
81	Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in patients with pretreated biliary tract cancer 2020 , 8,		49
80	Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma. <i>Scientific Reports</i> , 2020 , 10, 2086	4.9	19

79	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 107, 106-115	4	10
78	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. <i>Cancer Science</i> , 2020 , 111, 513-527	6.9	14
77	Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas. <i>Cancer Research and Treatment</i> , 2020 , 52, 1041-1049	5.2	2
76	Applied as an MRI-Based Reporter Gene. <i>Korean Journal of Radiology</i> , 2020 , 21, 726-735	6.9	1
75	Pre-screening of patient-reported symptoms using the Edmonton Symptom Assessment System in outpatient palliative cancer care. <i>European Journal of Cancer Care</i> , 2020 , 29, e13305	2.4	2
74	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919871126	5.4	15
73	Interprofessional Collaboration Between a Multidisciplinary Palliative Care Team and the Team Pharmacist on Pain Management. <i>American Journal of Hospice and Palliative Medicine</i> , 2019 , 36, 616-622	2.6	10
72	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Cancer Medicine</i> , 2019 , 8, 5023-5032	4.8	20
71	High levels of Daxx due to low cellular levels of HSP25 in murine cancer cells result in inefficient adenovirus replication. <i>Experimental and Molecular Medicine</i> , 2019 , 51, 1-20	12.8	
70	Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using 18 F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma. <i>Yonsei Medical Journal</i> , 2019 , 60, 604-610	3	11
69	Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer. <i>Oncologist</i> , 2019 , 24, e1108-e1114	5.7	9
68	Ecatenin activation down-regulates cell-cell junction-related genes and induces epithelial-to-mesenchymal transition in colorectal cancers. <i>Scientific Reports</i> , 2019 , 9, 18440	4.9	26
67	An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2019 , 24, 747-e218	5.7	41
66	Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 443-454	7.4	5
65	Outpatient Palliative Care and Aggressiveness of End-of-Life Care in Patients with Metastatic Colorectal Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2018 , 35, 166-172	2.6	5
64	The Development of Multidisciplinary Cancer Patient Education Counseling Questionnaire and Satisfaction Survey. <i>Korean Journal of Clinical Pharmacy</i> , 2018 , 28, 138-145	0.2	1
63	TGF- β downregulation-induced cancer cell death is finely regulated by the SAPK signaling cascade. <i>Experimental and Molecular Medicine</i> , 2018 , 50, 1-19	12.8	13
62	Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. <i>Medicine (United States)</i> , 2017 , 96, e7422	1.8	32

61	Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF- β induces anti-tumor immune activation. <i>Oncotarget</i> , 2017 , 8, 15858-15877	3.3	12
60	Down-Regulation of TGF- β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. <i>Yonsei Medical Journal</i> , 2017 , 58, 899-909	3	13
59	Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2017 , 49, 1127-1139	5.2	13
58	Efficacy and safety of localized concurrent chemoradiation therapy and sorafenib sequential therapy in advanced hepatocellular carcinoma: A prospective phase II trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15678-e15678	2.2	
57	Pseudoprogression in glioblastoma patients: the impact of extent of resection. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 559-66	4.8	11
56	Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2016 , 21, 351-64	5.4	12
55	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 545-557	4.0	630
54	Differences in the symptom distress between young adult and adult patients with advanced cancer admitted to acute palliative care unit.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 99-99	2.2	
53	Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnic: A Large Population-Based Observational Study. <i>Medicine (United States)</i> , 2016 , 95, e3472	1.8	18
52	Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells. <i>Cellular Signalling</i> , 2015 , 27, 807-17	4.9	10
51	Prognostic significance of standardized uptake value on preoperative 18 F-FDG PET/CT in patients with ampullary adenocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 841-7	8.8	8
50	Prediction of short- and long-term survival for advanced cancer patients after ICU admission. <i>Supportive Care in Cancer</i> , 2015 , 23, 1647-55	3.9	13
49	Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with conformal bone system: a preliminary report. <i>Yonsei Medical Journal</i> , 2015 , 56, 503-9	3	28
48	18 F-FDG PET/CT in hepatocellular carcinoma: detection of bone metastasis and prediction of prognosis. <i>Nuclear Medicine Communications</i> , 2015 , 36, 226-33	1.6	10
47	Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1024-31	4	9
46	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , 2015 , 47, 781-9	5.2	7
45	Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18 F-FDG PET/CT in Patients with Pancreatic Cancer. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 898-904	8.9	142
44	Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy. <i>Yonsei Medical Journal</i> , 2014 , 55, 1498-506	3	30

43	A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 5976-85	12.9	75
42	Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 199-207	4.8	13
41	Hepatitis B viral load to predict survival of HCC patients treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 188-188	2.2	1
40	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013 , 21, 1751-9	3.9	27
39	Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer. <i>Breast</i> , 2013 , 22, 1205-9	3.6	5
38	Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater. <i>Tohoku Journal of Experimental Medicine</i> , 2013 , 231, 21-8	2.4	7
37	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer. <i>Yonsei Medical Journal</i> , 2013 , 54, 1377-83	3	26
36	Two cases of humoral hypercalcemia of malignancy in metastatic cholangiocarcinoma. <i>Cancer Research and Treatment</i> , 2013 , 45, 145-9	5.2	6
35	Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. <i>Journal of Gastrointestinal Surgery</i> , 2012 , 16, 509-17	3.3	65
34	Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , 2012 , 13, 181-8	21.7	34 ⁰
33	Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. <i>Investigational New Drugs</i> , 2012 , 30, 1150-7	4.3	8
32	In vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) in solid pseudopapillary tumor of the pancreas. <i>Pancreas</i> , 2012 , 41, 498-500	2.6	4
31	A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. <i>Lung Cancer</i> , 2011 , 71, 55-9	5.9	39
30	Serous Cystic Neoplasm: Do We Have to Wait Till It Causes Trouble?. <i>Korean Journal of Hepato-biliary-pancreatic Surgery</i> , 2011 , 15, 134-8		3
29	Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. <i>Liver International</i> , 2011 , 31, 1144-9	7.9	5 ⁰
28	Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 659-67	4.9	43
27	Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using (18)F-FDG PET/CT and (99m)Tc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation. <i>Nuclear Medicine and Molecular Imaging</i> , 2011 , 45, 203-11	1.9	9
26	Outcome of adjuvant therapy for gallbladder cancer. <i>Oncology</i> , 2010 , 79, 168-73	3.6	26

25	Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients. <i>Oncology</i> , 2010 , 79, 293-300	3.6	12
24	Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. <i>Lung Cancer</i> , 2010 , 70, 77-81	5.9	14
23	Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2010 , 95, 303-7	5.3	21
22	Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. <i>Head and Neck</i> , 2010 , 32, 235-43	4.2	6
21	Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 425-31	3.5	
20	Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. <i>Cancer</i> , 2010 , 116, 1336-43	6.4	80
19	High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 2426-32	12.9	75
18	Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009 , 135, 1647-54	4.9	56
17	Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. <i>Journal of Neuro-Oncology</i> , 2009 , 91, 307-13	4.8	89
16	Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 65, 27-32	3.5	20
15	Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. <i>Oncology</i> , 2009 , 76, 1-9	3.6	33
14	Complete response of recurrent squamous cell carcinoma of the lung: dose the dose matter?. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 141-2	8.9	
13	The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. <i>Lung Cancer</i> , 2008 , 60, 393-400	5.9	11
12	Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2008 , 87, 361-6	5.3	8
11	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 75-81	3.5	9
10	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 157-65	3.5	11
9	Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 309-13	3.5	11
8	Standardization of the Korean version of Mini-Mental Adjustment to Cancer (K-Mini-MAC) scale: factor structure, reliability and validity. <i>Psycho-Oncology</i> , 2008 , 17, 592-7	3.9	45

7	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. <i>Acta Oncologica</i> , 2007 , 46, 547-9	3.2	0
6	Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. <i>Cancer</i> , 2007 , 109, 1845-950	6.4	24
5	Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute. <i>Journal of Surgical Oncology</i> , 2007 , 95, 461-8	2.8	67
4	VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. <i>Molecular Therapy</i> , 2007 , 15, 295-302	11.7	118
3	Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2528-33	2.2	129
2	A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. <i>Lung Cancer</i> , 2006 , 54, 365-70	5.9	16
1	A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma. <i>Yonsei Medical Journal</i> , 2005 , 46, 799-805	3	8